XSpray Pharma (Sweden) Performance
| XSPRAY Stock | SEK 45.80 4.40 10.63% |
The firm maintains a market beta of -0.47, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning XSpray Pharma are expected to decrease at a much lower rate. During the bear market, XSpray Pharma is likely to outperform the market. At this point, XSpray Pharma AB has a negative expected return of -0.0625%. Please make sure to check out XSpray Pharma's kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if XSpray Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days XSpray Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, XSpray Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 325.6 M | |
| Total Cashflows From Investing Activities | -105.8 M |
XSpray |
XSpray Pharma Relative Risk vs. Return Landscape
If you would invest 4,975 in XSpray Pharma AB on September 3, 2024 and sell it today you would lose (395.00) from holding XSpray Pharma AB or give up 7.94% of portfolio value over 90 days. XSpray Pharma AB is generating negative expected returns and assumes 3.6074% volatility on return distribution over the 90 days horizon. Simply put, 32% of stocks are less volatile than XSpray, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
XSpray Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XSpray Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XSpray Pharma AB, and traders can use it to determine the average amount a XSpray Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0173
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XSPRAY |
Estimated Market Risk
| 3.61 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.06 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XSpray Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XSpray Pharma by adding XSpray Pharma to a well-diversified portfolio.
XSpray Pharma Fundamentals Growth
XSpray Stock prices reflect investors' perceptions of the future prospects and financial health of XSpray Pharma, and XSpray Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XSpray Stock performance.
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| EBITDA | (87.82 M) | |||
| Cash And Equivalents | 192.85 M | |||
| Cash Per Share | 12.79 X | |||
| Total Debt | 1.19 M | |||
| Debt To Equity | 2.80 % | |||
| Book Value Per Share | 24.95 X | |||
| Cash Flow From Operations | (51.61 M) | |||
| Earnings Per Share | (5.18) X | |||
| Total Asset | 622.9 M | |||
About XSpray Pharma Performance
By analyzing XSpray Pharma's fundamental ratios, stakeholders can gain valuable insights into XSpray Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if XSpray Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if XSpray Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about XSpray Pharma AB performance evaluation
Checking the ongoing alerts about XSpray Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XSpray Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XSpray Pharma AB generated a negative expected return over the last 90 days | |
| XSpray Pharma AB has high historical volatility and very poor performance | |
| XSpray Pharma AB has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (96.7 M) with profit before overhead, payroll, taxes, and interest of 656 K. | |
| XSpray Pharma AB has accumulated about 192.85 M in cash with (51.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.79. | |
| Roughly 47.0% of the company outstanding shares are owned by insiders |
- Analyzing XSpray Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XSpray Pharma's stock is overvalued or undervalued compared to its peers.
- Examining XSpray Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XSpray Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XSpray Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XSpray Pharma's stock. These opinions can provide insight into XSpray Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for XSpray Stock analysis
When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |